RNS Announcements

NetScientific plc (“NetScientific” or the “Company” or the “Group”)     Notice of AGM and Annual Report & Accounts   London, UK – 24 May 2019 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that, in accordance with AIM Rules 20 and 26, the Group’s Annual Report and Accounts for the year ended 31 December 2018 and Notice of Annual …

NetScientific plc   (“NetScientific” or the “Group”)   NetScientific Full Year Results for the year ended 31 December 2018   London, UK – 22 May 2019 – NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, announces its full year audited results for the year ended 31 December 2018[1].   Financial highlights (including post-period end highlights)   Loss for the year from continuing …

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 25 April 2019 NetScientific plc (“NetScientific” or the “Company”) Resignation of CEO   NetScientific announces that it has accepted today the resignation of François Martelet as its CEO. François has resigned to assist the Company in reducing its central costs and to pursue other career opportunities. He will depart …

22 March 2019 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014   NetScientific plc (“NetScientific” or the “Company”) Sale of Wanda and Vortex   On 18 March 2019 NetScientific announced that it had received an indicative proposal from a third party regarding the sale of the Company’s shareholdings in Vortex Biosciences, Inc. (“Vortex”) and Wanda, Inc. …

London, UK – 08 November 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its US-based portfolio company, Vortex BioSciences, has presented a study that demonstrates the feasibility of combining its technology with impedance spectroscopy to improve the analysis of circulating tumour cells (CTCs).   The study presented at NanoBiotech Montreux 2018 introduces the coupling of Vortex technology with …

London, UK – 1 November 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its US-based portfolio company, Vortex BioSciences, has entered into a global manufacturing agreement with STRATEC Consumables GmbH (“STRATEC”) to produce a customised chip, a crucial component of Vortex’s automated liquid biopsy platform (VTX-1). STRATEC will also assist Vortex with scale-up to commercialisation with a view …

NetScientific plc (“NetScientific” or the “Company” or the “Group”)   NetScientific Interim Results for the six months ended 30 June 2018   London, UK – 28 September 2018: NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, today announces its interim results for the six months ended 30 June 2018.   Financial highlights   Loss after tax of £4.6m (H1 2017: loss £5.2m) …

London, UK – August 15, 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that portfolio company Wanda, which uses machine learning to help healthcare providers to better manage the risk and care of patients, has launched its new digital health application Wanda CareLink™. This application allows the Wanda Patient Management solution to be used on a wide variety of …

London, UK – July 18th, 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that portfolio company Wanda, which uses machine learning to help healthcare providers to better manage the risk and care of patients, has completed a significant enhancement of its Patient Management Platform to improve patient adherence to care plans. Use of Wanda’s existing platform had been shown …

London, UK – 6th June 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that its portfolio company Vortex Biosciences has appointed Bob Englert as Chief Executive Officer.   Bob, who is currently Chief Technology Officer, takes up the position with immediate effect, replacing Gene Walther, who has been Chief Executive Officer of Vortex Biosciences since January 2016. Gene has …

London, UK – 22nd May 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that, in accordance with AIM Rules 20 and 26, the Group’s Annual Report and Accounts for the year ended 31 December 2017 and Notice of Annual General Meeting have been sent to shareholders today and are available on the Company’s website in the Investor Relations section …

London, UK – May 21st, 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that Wanda and Health Resource Solutions (HRS), Wanda’s partner, have successfully achieved a reduction of 46% in the number of hospitals re-admissions in their high-risk Congestive Heart Failure patient population. Wanda’s real-time technology continuously assesses patient status and allows for detection of adverse events up to …

18 April 2018 NetScientific plc   Directors Dealing Notification   NetScientific plc (AIM:NSCI) (the “Company”), the transatlantic healthcare IP commercialisation group, announces that on 17 April 2018 it received notification that Sir Richard Sykes, Barry Wilson, and Steve Smith (the “Directors”), subscribed for New Ordinary Shares (the “Shares”) in the NetScientific Placing and Subscription (the “Placing”) at a price of 52.5 pence per Share, …

Data demonstrate the use of circulating tumour cells for identifying clinical biomarkers, such as EGFR mutations and PD-L1 expression, in patients with Non-Small Cell Lung Cancer (NSCLC) London, UK – 16 April 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its US-based portfolio company, Vortex BioSciences, a leading liquid biopsy company, is presenting compelling new data at the …

BioTrinity – Panel: AIM v NASDAQ v European Listing – What’s best for you – London (24 April) Approaching the 12th consecutive year, the goal of BioTrinity is to create an ideal network and partnering platform for the global life sciences industry under one roof, ultimately to help shape our healthcare future. The theme for BioTrinity 2018 is ‘Next Generation Healthcare’ which will …

NetScientific plc   (“NetScientific” or the “Group”)   NetScientific Full Year Results for the year ended 31 December 2017   London, UK – 29 March 2018 – NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, announces its full year audited results for the year ended 31 December 2017[1]   Financial highlights (including post-period end highlights)   Narrowed losses after tax to £9.4 million …

London, UK – March 19th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that Wanda Health, its portfolio company, is expanding into orthopedics through a new partnership with HRS Home Health (“HRS”).   Wanda’s predictive analytics and artificial intelligence solutions already provide remote management solutions for chronic conditions in heart and respiratory health. The partnership with HRS, a Wanda …

London, UK – 13 March 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, notes that its portfolio company, Vortex BioSciences, has announced a collaboration with BioView Ltd (TASE:BIOV), a provider of automated cell imaging and analysis solutions.   The collaboration will enable Vortex and Bioview to create integrated workflows that will allow the collection of intact CTCs from blood samples …

London, UK – 09 February 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, notes that its portfolio company, Vortex BioSciences, has announced a report published by Nature Scientific Reports. The peer reviewed report, titled “Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer” describes the use of the Vortex’s technology in capturing circulating tumour cells (CTCs), …

London, UK – 16 January 2018 – NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, today announces an update on its core portfolio. Over 2018 NetScientific will continue the commercial and corporate development of all its portfolio assets to maximise value. Glycotest: Glycotest successfully completed a clinical evaluation of its HCC Panel for Hepatocellular Carcinoma (HCC), the most common form of liver cancer. …

London, UK – December 12th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces the issue by the U.S. Patent and Trademark Office of two new patents exclusively licensed to its portfolio company, Wanda. The patents will significantly extend protection for the core technology used in Wanda’s software application for remote health and patient management. The patents, titled, “Apparatus, System, …

London, UK – 7 November 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, notes that its portfolio company, Vortex BioSciences, today announced its first direct commercial sale of its VTX-1 Liquid Biopsy System, a fully automated benchtop system for collecting intact Circulating Tumour Cells (CTCs).   Vortex’s VTX-1 Liquid Biopsy System automates the capture and collection of viable CTCs directly …

London, UK – November 3rd 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that HRS Home Health (HRS) is expanding their use of Wanda to all of their home health patients. This follows a successful trial evaluation involving high-risk, co-morbid Congestive Heart Failure patients.   Commenting on the news, NetScientific’s Chief Executive Officer and Chairman of Wanda, Francois R. …

London, UK – 1 November 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces an update from its portfolio company, Vortex BioSciences, which today announced the publication of “Workflow optimization of whole genome amplification and targeted panel sequencing for CTC mutation detection” in Nature Partner Journals (npj) Genomic Medicine on 1 November 2017. Source: https://tinyurl.com/ybhuzpu4 DOI Number: 10.1038/s41525-017-0034-3 The peer-reviewed …

London, UK – October 27th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, provides an update on its portfolio company ProAxsis, which today announces that it has entered into a clinical trial partnership with National Jewish Health (“NJH”), the leading respiratory hospital in the United States. Under the agreement ProAxis and NJH will work together in validating ProAxsis’ ProteaseTag® point-of-care …

London, UK – 25 October 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that Jonathan Paisner, Non-Executive Director, will be stepping down from his position on the Board with immediate effect, with the 25th October as his final day. Commenting on the news, Francois Martelet, Chief Executive Officer of NetScientific said: “The Board of Directors and I would like …

London, UK – October 2nd 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces the issue by the U.S. Patent and Trademark Office of a new patent exclusively licensed to its portfolio company, Wanda. The patent will significantly extend protection for the core technology used in Wanda’s software application for remote health and patient management. The patent, titled, “Context-aware prediction …

NetScientific plc (“NetScientific” or the “Company” or the “Group”)   NetScientific Interim Results for the six months ended 30 June 2017     London, UK – 28 September 2017: NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, today announces its interim results for the six months ended 30 June 2017.   Operational highlights   First successful exit for NetScientific following sale of …

London, UK – 7 September 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that it will report its financial results for the 6 months ended 30 June 2017 on Thursday 28 September 2017.   Francois Martelet, Chief Executive Officer, and Ian Postlethwaite, Chief Financial Officer, will hold a presentation and conference call for analysts on the day of results …

RNS Number : 7628I NetScientific PLC 21 June 2017 NetScientific plc (“NetScientific” or the “Company” or the “Group”) Result of Annual General Meeting London, UK – June 21st 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic biomedical and healthcare technology group, announces that all resolutions proposed at today’s Annual General Meeting, were duly passed. #  #  # For more information, please contact:     …

RNS Number : 3190I NetScientific PLC 16 June 2017 The following is to be read in replacement of the Holdings In Company announcement released on 15 June 2017 at 14:52 under RNS number 2326I. The following sections of the notification have been amended:   7.Threshold(s) that is/are crossed or reached   For filings with the FCA include the annex   For filings with …

NetScientific plc 170526 Annual Report and AGM (Final) (“NetScientific” or the “Company” or the “Group”) Notice of AGM and Annual Report & Accounts London, UK – May 26th 2017 – London, UK – May 26 th 2017 – NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation Group announces that, in accordance with AIM Rules 20 and 26, the Group’s Annual Report and Accounts …

04:18 24 May 2017 http://www.proactiveinvestors.com/companies/news/178249/netscientific-business-vortex-bio-kicks-off-lung-cancer-proof-of-concept-trial-178249.html These studies are designed to provide proof of principle that biomarkers used for tumour biopsises can be adapted for circulating tumour cells (CTCs). Vortex aims to collect circulating turmour cells NetScientific PLC (LON:NSCI) portfolio company Vortex Biosciences has initiated two clinical research studies with Californian university UCLA in patients with Non-Small Cell Lung Cancer (NSCLC). These studies are …

Proactive Investors One2One Investor Forum – London Redx Pharma Plc | Summit Therapeutics PLC | Netscientific PLC http://www.proactiveinvestors.com/register/event_details/104 Jun 15th 2017, 6.00 pm – Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details …

RNS Number : 0032J NetScientific PLC 06 September 2016 (“NetScientific” or the “Company” or the “Group”)     Notice of Interim Results   London, UK – 6 September 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that it will report its interim results for the six months ended 30 June 2016 on Tuesday 27 September2016. An analyst presentation will …

RNS Number : 4527F NetScientific PLC 28 July 2016 (“NetScientific” or the “Company” or the “Group”)   Change of Adviser London, UK – 28 July 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic biomedical and healthcare technology  group, is pleased to announce the appointment of Stifel Nicolaus Europe Limited as Nominated Adviser and Broker to the Company with immediate effect. – Ends –   …

RNS Number : 2799C NetScientific PLC 27 June 2016 (“NetScientific” or the “Company” or the “Group”) Grant of Options to Director London, UK – 27th June 2016 – NetScientific plc (“NetScientific”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, today announced that on 24th June 2016, options over ordinary shares of 5p each were granted to Ian Postlethwaite and Stephen Smith as detailed below. …

RNS Number : 3020B NetScientific PLC 15 June 2016 (“NetScientific” or the “Company” or the “Group”)   Results of Annual General Meeting London, UK – 15th June 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic biomedical and healthcare technology  group, announces that all resolutions proposed at today’s Annual General Meeting, were duly passed.   NetScientific has over the past year undergone a transformation, with …

RNS Number : 0709B NetScientific PLC 14 June 2016  14 June 2016   NetScientific plc (“NetScientific” or the “Group”)   NetScientific hosts Capital Markets Day to outline its strategy and showcase its portfolio of assets   London, UK – 14 June 2016 – NetScientific plc (AIM: NSCI), the transatlantic healthcare technology group, is today hosting a Capital Markets Day in London to outline the comprehensive …

RNS Number : 8030A NetScientific PLC 10 June 2016 (“NetScientific” or the “Company” or the “Group”)   Netscientific Confirms Start Date for Ian Postlethwaite as CFO   London, UK – 10 June 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic biomedical and healthcare technology group, is pleased to confirm that further to the Company’s announcement of his appointment on 5th April 2016, new Chief …

RNS Number : 3753A NetScientific PLC 07 June 2016   NetScientific plc (“NetScientific” or the “Company” or the “Group”) NetScientific Portfolio PDS Biotechnology presents at BIO 2016 NetScientific makes further investment in PDS Biotechnology London, UK – 7 June 2016 – NetScientific plc (AIM: NSCI), the transatlantic healthcare technology group, is pleased to note that its therapeutics portfolio company, PDS Biotechnology, will today be presenting …

RNS Number : 9816Y NetScientific PLC 23 May 2016 NetScientific (“NetScientific” or the “Company” or the “Group”)  Notice of AGM and Annual Report & Accounts   London, UK – 23 May 2016 – NetScientific plc (AIM:NSCI), the transatlantic healthcare technology group announces that, in accordance with AIM Rules 20 and 26, the Group’s Annual Report and Accounts for the year ended 31 December 2015 and …

RNS Number : 4509V NetScientific PLC 18 April 2016 NetScientific (“NetScientific” or the “Company” or the “Group”)     NetScientific portfolio company Vortex Biosciences introduces novel fully automated circulating tumour cell enrichment instrument VTX-1 at AACR   London, UK – 18 April 2016 – NetScientific plc (AIM:NSCI), the transatlantic healthcare technology group, notes that its portfolio company, Vortex Biosciences, will preview VTX-1, a fully …

RNS Number : 4343U NetScientific PLC 07 April 2016  7 April 2016   NetScientific plc (“NetScientific” or the “Group”)   NetScientific Full Year Results year ended 31 December 2015   London, UK – 7 April 2016 – NetScientific plc (AIM: NSCI), the transatlantic healthcare technology group, announces its audited Full Year results for the year ended 31 December 2015.   Operational highlights:   ·      Appointment …

RNS Number : 1367U NetScientific PLC 05 April 2016 (“NetScientific” or the “Company” or the “Group”)   Netscientific Appoints Ian Postlethwaite as Chief Financial Officer London, UK – 5th April 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic biomedical and healthcare technology  group, is pleased to announce that Ian Postlethwaite has accepted the role as Chief Financial Officer.  Ian will join the Company and …

RNS Number : 1205T NetScientific PLC 24 March 2016 (“NetScientific” or the “Company” or the “Group”)   Notice of Results London, UK – 24 March 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic biomedical and healthcare technology group, announces that it will report its final results for the 12 months ended 31 December 2015 on 07 April 2016. An analyst presentation will be held …

RNS Number : 2148S NetScientific PLC 16 March 2016      (“NetScientific” or the “Group”)     Wanda Forms Scientific Advisory Board to Provide Strategic Guidance London, UK – 16 March 2016 – NetScientific plc (AIM: NSCI), the transatlantic biomedical and healthcare technology group, notes its Digital Health Portfolio company, Wanda, has announced the formation of a Scientific Advisory Board to provide thought leadership and …

RNS Number : 2859R NetScientific PLC 07 March 2016 NetScientific plc Adoption of the reduced disclosure framework within Financial Reporting Standard (FRS) 102 London, UK – 7th March 2016 – NetScientific plc (“NetScientific”. AIM: NSCI), the transatlantic biomedical and healthcare technology group, today announces that following the publication of FRS 100 ‘Application of Financial Reporting Requirements’ by the Financial Reporting Council, it is required to …

RNS Number : 6459Q NetScientific PLC 01 March 2016   NetScientific plc   Vortex BioSciences co-founder receives US Presidential award for groundbreaking “Liquid Biopsy” technique London, UK – 1 March 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group notes its operating subsidiary, Vortex Biosciences’ (‘Vortex’) announcement about its co-founder receiving the US Presidential Early Career Award …

RNS Number : 3883Q NetScientific PLC 29 February 2016 NetScientific plc Wanda™ partners with leading US Hospital Group Dignity Health™ to launch oncology decision support software platform – OncoVerse™ London, UK – 29 February 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, announces that its operating subsidiary, Wanda, has signed a collaborative deal with one of …

RNS Number : 2646P NetScientific PLC 17 February 2016 NetScientific plc   NetScientific appoints Professor Stephen Smith as Non-Executive Director   London, UK – 17 February 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, appoints Professor Stephen Smith as Non-Executive Director, with effect from today. Professor Smith will also join both the audit and remuneration committees. …

RNS Number : 4149O NetScientific PLC 08 February 2016 NetScientific plc   Grant of Options to Director   London, UK – 8 February 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group today announced that on 4 February 2016, options over a total of 200,000 ordinary shares of 5p each were granted to Francois Martelet.   Director …

RNS Number : 9451M NetScientific PLC 26 January 2016 NetScientific plc   Board Change   London, UK – 26 January 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group today announced the resignation from the board of Peter Thoms, Chief Financial Officer. Peter leaves the company in order to pursue new challenges, particularly in the technology sector. …

RNS Number : 6412K NetScientific PLC 04 January 2016   NetScientific plc     WANDA signs contract with leading US home nursing and therapy service provider, HRS, to provide better care for patients with chronic conditions   London, UK – 4 January 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, announces that portfolio company, WANDA …

RNS Number : 8771I NetScientific PLC 14 December 2015 NetScientific plc   Ex Novartis Diagnostics president, Gene Walther is appointed CEO of Vortex BioSciences and NetScientific’s Head of Diagnostics   Board Change   London, UK – 14 December 2015 – NetScientific plc (AIM: NSCI, ‘NetScientific’ or the ‘Group’), the transatlantic biomedical and healthcare technology group, continues its restructuring towards a sector franchise model with …

RNS Number : 7571F NetScientific PLC 16 November 2015  NetScientific PLC (“NetScientific” or the “Group”)     London, UK – 16 November 2015: NetScientific PLC (AIM: NSCI.L), a transatlantic biomedical healthcare group, announces that it will today apply to admit, in total, 54,167 ordinary shares of 5p each to trading on AIM. Admission is expected on 20 November 2015 and these shares will rank pari …

RNS Number : 2698F NetScientific PLC 11 November 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acquisition or disposal of qualifying financial …

RNS Number : 1137F NetScientific PLC 10 November 2015 NetScientific PLC (“NetScientific” or the “Group”)   Grant of Options to Director   London, UK – 10 November 2015: NetScientific plc (AIM:NSCI), a transatlantic biomedical healthcare group, announces that on 9 November 2015, options over a total of 359,020 Ordinary Shares of 5p each were granted to Francois Martelet.   Director Position Number of Options Granted …

RNS Number : 8824E NetScientific PLC 06 November 2015 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.    …

RNS Number : 7886E NetScientific PLC 06 November 2015 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.    …

RNS Number : 4417E NetScientific PLC 03 November 2015 For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific Plc 2 Reason for the notification (please tick the appropriate box or boxes): …

RNS Number : 9468C NetScientific PLC 21 October 2015 NetScientific plc (“NetScientific” or the “Company”)   Posting of Circular   21 October 2015   Further to the announcement made by the Company on 1 October 2015, NetScientific announces that a Circular has today been published and posted to shareholders in relation to the proposed placing to raise approximately £18.0 million (before expenses), the additional …

RNS Number : 8339A NetScientific PLC 01 October 2015   NetScientific plc (‘NetScientific or the ‘Company’ or the ‘Group’)   Half Year Results for the six months ended 30 June 2015     London, UK – 1 October 2015: NetScientific (AIM: NSCI), the transatlantic biomedical and healthcare technology group today announced its half year results for the six months ended 30 June 2015.   …

RNS Number : 8342A NetScientific PLC 01 October 2015 THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO …

RNS Number : 4497Z NetScientific PLC 18 September 2015 NetScientific plc   Divestment of shareholding in Frontier BioSciences and realignment of resources towards our primary portfolio     London, UK – 18 September 2015 – NetScientific plc (“NetScientific” or “the Company”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, has agreed to sell NetScientific UK Limited’s (“NS UK”) 49.9% holding in Frontier BioSciences …

RNS Number : 2576Z NetScientific PLC 16 September 2015   TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific Plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisition or disposal of qualifying …

RNS Number : 0312Z NetScientific PLC 15 September 2015   NetScientific plc   Vortex BioSciences granted critical patent for its Liquid Biopsy technology London, UK – 15 September 2015 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, announces that one of its key  portfolio companies, Vortex BioSciences Inc., has been granted a critical patent on its …

RNS Number : 5652Y NetScientific PLC 09 September 2015   NetScientific plc     NetScientific announces the key appointment of Steve Curd as CEO of Wanda, Inc.   London, UK – 9 September 2015 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, announces the appointment of Steve Curd as CEO of its portfolio company, Wanda, and …

RNS Number : 3824V NetScientific PLC 07 August 2015   NetScientific plc   NetScientific divests non-core assets to align its healthcare portfolio    London, UK – 7 August 2015 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, announces that as part of an ongoing review of its portfolio, it has started to divest certain projects that …

RNS Number : 9521U NetScientific PLC 04 August 2015 NetScientific plc   ProAxsis launches first-in-class ProteaseTagTM test for Cystic Fibrosis and Chronic Obstructive Pulmonary Disease   London, UK – 4 August 2015 – NetScientific portfolio company, ProAxsis, a medical diagnostics spin-out from Queen’s University Belfast, has officially launched its proprietary first-in-class ProteaseTag™ immunoassay kits to research labs and announces its first two customer orders, …

RNS Number : 0582T NetScientific PLC 15 July 2015     NetScientific plc   Significant European patent granted on Glucosense Diagnostics technology     London, UK – 15 July 2015 – NetScientific plc (“NetScientific” or “the Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, highlights University of Leeds’ announcement about its jointly funded portfolio company, Glucosense Diagnostics (Glucosense). Today the award of …

RNS Number : 8379Q NetScientific PLC 22 June 2015       NetScientific plc   Results of Annual General Meeting     London, UK – 22 June 2015 – NetScientific plc (“NetScientific” or “the Group”, AIM: NSCI), the biomedical and healthcare technology group, announces that all resolutions proposed at today’s Annual General Meeting have been duly passed.   As previously announced, Francois Martelet, the …

RNS Number : 7804Q NetScientific PLC 22 June 2015 NetScientific plc Annual General Meeting London, UK – 22 June 2015 – NetScientific plc (“NetScientific” or “the Group”, AIM: NSCI), the biomedical and healthcare technology group, is holding its Annual General Meeting (AGM) today at 11am. Ahead of this meeting Chairman, Sir Richard Sykes, will make the following comments: “2015 has been transformational for the …

RNS Number : 4404P NetScientific PLC 05 June 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific Plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisition or disposal of qualifying financial …

RNS Number : 4401P NetScientific PLC 05 June 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific Plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisition or disposal of qualifying financial …

RNS Number : 4400P NetScientific PLC 05 June 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific Plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisition or disposal of qualifying financial …

RNS Number : 4038P NetScientific PLC 05 June 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acquisition or disposal of qualifying financial …

RNS Number : 4034P NetScientific PLC 05 June 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NETSCIENTIFIC PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights YES An acquisition or disposal of qualifying financial …

RNS Number : 5095O NetScientific PLC 28 May 2015 NetScientific plc (“NetScientific” or the “Group”)   PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy   London, UK – 28 May 2015 – NetScientific (AIM: NSCI) notes that portfolio company, PDS Biotechnology Corp., has announced positive preliminary data showing that its lead cancer immunotherapy treatment, PDS0101, has generated strong T-cell responses in …

RNS Number : 4055N NetScientific PLC 18 May 2015 NetScientific plc (“NetScientific” or the “Group”)   Annual Report and Accounts   London, UK – 18 May 2015 – NetScientific (AIM: NSCI), the biomedical and healthcare technology group, announces that, in accordance with AIM Rules 20 and 26, the Group’s Annual Report and Accounts for the year ended 31 December 2014 and Notice of Annual …

RNS Number : 2602N NetScientific PLC 15 May 2015   NetScientific plc (“NetScientific” or the “Group”)   Capital Markets Day     London, UK – 15 May 2015 – NetScientific plc (AIM: NSCI), the biomedical and healthcare technology group, is holding a Capital Markets Day for institutional investors and analysts today in London. The event includes a presentation on NetScientific’s refined strategy which has …

RNS Number : 7136M NetScientific PLC 11 May 2015   NetScientific plc (“NetScientific” or the “Group”)   NetScientific appoints Dr. François R. Martelet as Chief Executive Officer   London, UK – 11 May 2015 – NetScientific (AIM: NSCI), the biomedical and healthcare technology group, announces the appointment of Dr François R. Martelet as Chief Executive Officer and Board Director.   Dr. Martelet will join …

RNS Number : 4149M NetScientific PLC 07 May 2015     NetScientific plc (“NetScientific” or the “Group”)   NetScientific invests in wearable digital health company, Neumitra   London, UK – 7 May 2015 – NetScientific (AIM: NSCI), the biomedical and healthcare technology group, today announced its investment in Neumitra, a digital health company, developing wearable devices and smart software applications for the real-time management of …

RNS Number : 9480L NetScientific PLC 01 May 2015 NetScientific plc (“NetScientific” or the “Group”)   NetScientific forms digital health company with US hospital group, Meridian Health   Triventis Health LLC will commercialise advanced patient management solutions   1 May 2015: NetScientific (AIM: NSCI), the biomedical and healthcare technology group, has  formed a new digital health sales and marketing subsidiary company, Triventis Health LLC …

RNS Number : 6699L NetScientific PLC 29 April 2015       NetScientific plc (“NetScientific” or the “Group”)   Capital Markets Day     London, UK – 29 April 2015 – NetScientific plc (AIM: NSCI), the biomedical and healthcare technology group, will be holding a Capital Markets Day on Friday 15 May 2015 at 10.30am – 3.00pm in London to provide an update on the …

RNS Number : 0844J NetScientific PLC 01 April 2015 NetScientific plc Appointment of Adviser   London, UK – 1 April 2015 – NetScientific plc (AIM: NSCI), the biomedical and healthcare technology group, announces that it has appointed Investec Bank plc as its Nominated Adviser and sole Broker with immediate effect.   -Ends-   About NetScientific   NetScientific is a biomedical and healthcare technology group …

RNS Number : 2522I NetScientific PLC 24 March 2015 NetScientific plc (‘NetScientific’ or the ‘Group’)   NetScientific Full Year results: Significant Progress in core Portfolio Companies Wanda Health and Vortex BioSciences. First commercial launches expected during 2015   London, UK – 24 March 2015 – NetScientific (AIM: NSCI), the biomedical and healthcare group, announces its results for the year ended 31 December 2014. Highlights …

RNS Number : 0638I NetScientific PLC 20 March 2015 NetScientific plc (“NetScientific” or the “Group”) Notice of Full Year Results   London, UK – 20 March 2015 – NetScientific plc (AIM: NSCI), the biomedical and healthcare technology group, will announce its full year results for the year ended 31 December 2014 on Tuesday 24 March 2015.   A presentation for analysts will be held …

RNS Number : 9575F NetScientific PLC 26 February 2015     NetScientific plc (“NetScientific” or the “Group”)   Appointment to the Board   NetScientific appoints Jonathan Paisner as Non-Executive Director   26 February 2015: NetScientific (AIM: NSCI), the biomedical and healthcare technology group is pleased to announce that Jonathan Paisner will join the Board with immediate effect as a non-executive director.   Jonathan is …

RNS Number : 4483C NetScientific PLC 16 January 2015   NetScientific plc (“NetScientific” or the “Group”)   NetScientific announces departure of Chief Executive Officer   16 January 2015: NetScientific (AIM:NSCI), the biomedical and healthcare technology group, today announces that Farad Azima has been removed from the positions of Chief Executive Officer and a Director of NetScientific with immediate effect. The Board has unanimously agreed …

RNS Number : 5259B NetScientific PLC 07 January 2015 NetScientific plc (“NetScientific” or the “Group”)   NetScientific teams up with KU Leuven on research programmes in early cancer detection, epigenomic analysis and fiber-optics diagnostics   7th January 2015: NetScientific (AIM: NSCI), the biomedical and healthcare technology group, today announced that it has entered into three research programmes with KU Leuven in Belgium.   The …

RNS Number : 5253B NetScientific PLC 07 January 2015 NetScientific plc (“NetScientific” or the “Group”)   NetScientific announces investment in DName-iT bringing important improvements to diagnostic Next Generation Sequencing     7th January 2015: NetScientific (AIM:NSCI), the biomedical and healthcare technology group, today announced its investment in DName-iT NV (“DName-iT”) a spin-out from KU Leuven in Belgium   As a subsidiary company of NetScientific, …

RNS Number : 4502Z NetScientific PLC 11 December 2014   NetScientific plc (‘NetScientific’ or ‘the Group’)   NetScientific enters into an alliance with Healthbox to invest in new early-stage healthcare companies   11 December 2014: NetScientific (AIM:NSCI), the global biomedical and healthcare technology group, today announced entering into an alliance with Healthbox, a leading healthcare business accelerator, to support the development of early-stage healthcare …

RNS Number : 0499Z NetScientific PLC 08 December 2014   NetScientific plc (‘NetScientific’ or ‘the Group’)   NetScientific invests in Breakout Labs’ portfolio company EpiBone   8 December 2014: NetScientific (AIM:NSCI), the global biomedical and healthcare technology group, today announced it has made an investment in EpiBone, a revolutionary bone reconstruction company that allows patients to “grow their own bone”. It is the Group’s fourth …

RNS Number : 2346X NetScientific PLC 17 November 2014   TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii netScientific Group 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights Yes An acquisition or disposal of qualifying …

RNS Number : 2097X NetScientific PLC 17 November 2014   TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acquisition or disposal of qualifying …

RNS Number : 3461T NetScientific PLC 03 October 2014   NetScientific plc (‘NetScientific’ or ‘the Group’)   NetScientific’s subsidiary, Glycotest Begins a New Research Collaboration with Oncimmune   Application of Combined Diagnostic Technologies Aimed at Improving Early Detection of Liver Cancer   3 October 2014: NetScientific (AIM: NSCI), the global biomedical and healthcare technology group today announces its portfolio company Glycotest, Inc. has entered …

RNS Number : 3136S NetScientific PLC 23 September 2014     NetScientific plc (‘NetScientific’ or ‘the Company’ or ‘the Group’)   Half-Yearly Report     23 September 2014: NetScientific (AIM: NSCI), the global biomedical and healthcare technology group today announces its half yearly report for the six months ended 30 June 2014.   Highlights   § Significant progress made in advancing the technologies in …

RNS Number : 9340R NetScientific PLC 17 September 2014               NetScientific plc (‘NetScientific’ or ‘the Company’)    Notification of Half Yearly Report Date     NetScientific (AIM: NSCI), the biomedical and healthcare technology investment group, will announce its half yearly report for the six months ended 30 June 2014 on Tuesday, 23 September 2014.   A presentation for …

RNS Number : 6569N NetScientific PLC 29 July 2014   NetScientific announces significant shareholder name change NetScientific plc (AIM:NSCI, ‘NetScientific’ or ‘The Group’), the biomedical and healthcare technology investment group, has been informed by one of the Group’s significant shareholders, Quantadyne Limited, which owns 9.6% of the Company’s equity, that it has changed its name to White Mustard Investments. For further information, please contact: …

RNS Number : 8531M NetScientific PLC 21 July 2014   TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights Yes An acquisition or disposal of qualifying …

RNS Number : 1064M NetScientific PLC 11 July 2014   TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acquisition or disposal of qualifying …

RNS Number : 5298L NetScientific PLC 04 July 2014   TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii NetScientific plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acquisition or disposal of qualifying …

RNS Number : 1276L NetScientific PLC 02 July 2014       NetScientific plc (‘NetScientific’ or the ‘Group’) Research Programme in DNA Sequencing     NetScientific (AIM:NSCI), the biomedical and healthcare technology investment group, is pleased to announce that, to complement and reinforce its personalised medicine platform, Nanopore-II (a new US division of NetScientific) has secured an important research programme in DNA sequencing with …

RNS Number : 1943J NetScientific PLC 09 June 2014   NetScientific plc NetScientific plc (AIM:NSCI, ‘NetScientific’ or ‘the Company’), the biomedical and healthcare technology investment group, today announces that it has entered into a new service agreement with Peter Thoms, a director of the Company, terminable on six months’ notice by either party. Following this, the Remuneration Committee has today awarded him options to …

RNS Number : 5261H NetScientific PLC 20 May 2014 NetScientific plc AGM Statement   At the Company’s Annual General Meeting to be held today at 11.30 a.m. the Chairman, Sir Richard Sykes, will make the following statement to shareholders:   “I am pleased to report that the year has started well. We have continued to invest in our key subsidiaries, with particular focus on …

RNS Number : 6276H NetScientific PLC 20 May 2014   NetScientific plc Result of AGM   NetScientific is pleased to announce that at its Annual General Meeting held earlier today all resolutions proposed in the Notice of the Meeting were duly passed.   For further information, please contact:     Liberum (Nomad & Broker)   Chris Bowman / Christopher Britton / Thomas Bective Tel: …

RNS Number : 3950H NetScientific PLC 19 May 2014   NetScientific announces research agreement with Harvard University     NetScientific plc (AIM:NSCI, ‘NetScientific’ or ‘The Group’), the biomedical and healthcare technology investment group, is pleased to announce that Vortex, its Palo Alto based spinout, has signed an agreement with the Rowland Institute at Harvard University.  Under the research agreement, the Rowland Institute will explore …

RNS Number : 5906G NetScientific PLC 08 May 2014       NetScientific plc (‘NetScientific’ or the ‘Group’) Posting of Annual Report and Notice of AGM   8 May 2014   NetScientific (AIM:NSCI), the biomedical and healthcare technology investment group, announces that the Group’s Report and Accounts, for the period ended 31 December 2013, and Notice of AGM have been posted to shareholders. A …

RNS Number : 1817D NetScientific PLC 26 March 2014   NetScientific Partners with Peter Thiel’s Breakout Labs to Increase Support for Companies at the Forefront of Scientific Innovation     NetScientific plc (AIM:NSCI, ‘NetScientific’ or ‘The Group’), the biomedical and healthcare  technology investment group, is pleased to announce a strategic alliance with the San Francisco-based Breakout Labs, Peter Thiel’s revolving philanthropic fund that supports …

RNS Number : 6281C NetScientific PLC 19 March 2014       NetScientific plc (‘NetScientific’ or the ‘Group’) Preliminary results for the 12 months ended 31 December 2013   19 March 2014   NetScientific (AIM:NSCI), the biomedical and healthcare technology investment group, has published its results for the year ended 31 December 2013.     Highlights   § £30.0 million (net of costs £28.6) …

RNS Number : 2763C NetScientific PLC 13 March 2014   Netscientific plc (‘Netscientific’ or ‘the Company’)   Notification of Results   Netscientific, the biomedical and healthcare technology investment group, will announce its full year results for the year ended 31 December 2013 on Wednesday 19 March 2014.   A presentation for analysts, hosted by the management team, will be held at 9:00am GMT on Wednesday 19th March 2014. …

RNS Number : 1835P NetScientific PLC 30 September 2013   30 September 2013   NetScientific plc (“NetScientific” or the “Group”)   Director Dealings   NetScientific, the healthcare medical technology company, announces that on 27 September 2013 it received notification that, on 27 September 2013, Barry Wilson, Non Executive Director of the Group, purchased 6,150 ordinary shares of 5p each in the capital of the Group …

RNS Number : 0585P NetScientific PLC 27 September 2013   NetScientific plc (‘NetScientific’ or the ‘Group’) Interim results for the six months ended 30 June 2013 27 September 2013 NetScientific (AIM:NSCI), the healthcare medical technology company, is pleased to announce its maiden unaudited interim results for the six months ended 30 June 2013. Financial Highlights ·     Pre-tax loss for the period of  £1,040k (H1 …

RNS Number : 0184O NetScientific PLC 16 September 2013   NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN, AUSTRALIA OR THE REPUBLIC OF IRELAND OR IN, INTO OR FROM ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION   For Immediate Release 16 September 2013   NetScientific plc (“NetScientific” or the “Group”)   …